1. Home
  2. NTZ vs NRXS Comparison

NTZ vs NRXS Comparison

Compare NTZ & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natuzzi S.p.A.

NTZ

Natuzzi S.p.A.

HOLD

Current Price

$2.52

Market Cap

29.4M

ML Signal

HOLD

Logo Neuraxis Inc.

NRXS

Neuraxis Inc.

HOLD

Current Price

$3.82

Market Cap

25.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTZ
NRXS
Founded
1959
2011
Country
Italy
United States
Employees
N/A
N/A
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
29.4M
25.8M
IPO Year
1993
2023

Fundamental Metrics

Financial Performance
Metric
NTZ
NRXS
Price
$2.52
$3.82
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
8.8K
854.7K
Earning Date
01-01-0001
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$358,555,673.00
$3,362,320.00
Revenue This Year
N/A
$31.05
Revenue Next Year
N/A
$137.61
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.89
52 Week Low
$2.15
$1.33
52 Week High
$5.50
$6.20

Technical Indicators

Market Signals
Indicator
NTZ
NRXS
Relative Strength Index (RSI) 48.45 68.15
Support Level $2.24 $2.63
Resistance Level $2.69 $4.25
Average True Range (ATR) 0.21 0.33
MACD 0.01 0.13
Stochastic Oscillator 49.29 75.43

Price Performance

Historical Comparison
NTZ
NRXS

About NTZ Natuzzi S.p.A.

Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.

About NRXS Neuraxis Inc.

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Share on Social Networks: